Cargando…

SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist

Detalles Bibliográficos
Autores principales:	Bozonnat, Alizée, Assan, Florence, LeGoff, Jérôme, Bourrat, Emmanuelle, Bachelez, Hervé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235915/ https://www.ncbi.nlm.nih.gov/pubmed/34176064 http://dx.doi.org/10.1007/s10875-021-01076-6

Ejemplares similares

Poussée sévère de DITRA causée par le SARS-CoV-2
por: Bozonnat, Alizée, et al.
Publicado: (2021)

Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents
por: Hospach, Toni, et al.
Publicado: (2019)

P02-002 - IL36RN mutations in patients with DITRA
por: Arostegui, JI, et al.
Publicado: (2013)

IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD
por: Baker, Jonathan R., et al.
Publicado: (2022)

Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin
por: Cuperus, Edwin, et al.
Publicado: (2018)

TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency
por: Fukushima, Hidehiko, et al.
Publicado: (2020)

Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist
por: Macleod, Tom, et al.
Publicado: (2016)

IL-36 receptor antagonist deficiency resulted in delayed wound healing due to excessive recruitment of immune cells
por: Saito, Kenta, et al.
Publicado: (2020)

Neutrophil extracellular traps are involved in enhanced contact hypersensitivity response in IL-36 receptor antagonist-deficient mice
por: Hasegawa, Yurie, et al.
Publicado: (2022)

Identification of small‐molecule elastase inhibitors as antagonists of IL‐36 cytokine activation
por: Sullivan, Graeme P., et al.
Publicado: (2018)

A Case of Old Age-Onset Generalized Pustular Psoriasis with a Deficiency of IL-36RN (DITRA) Treated by Granulocyte and Monocyte Apheresis
por: Tominaga, Chiharu, et al.
Publicado: (2015)

Altered serum levels of IL-36 cytokines (IL-36α, IL-36β, IL-36γ, and IL-36Ra) and their potential roles in Guillain-Barré syndrome
por: Zhao, Zhikang, et al.
Publicado: (2020)

IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist
por: Baker, Kevin, et al.
Publicado: (2022)

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis
por: Todorović, Viktor, et al.
Publicado: (2019)

AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists
por: Moody, Terry W., et al.
Publicado: (2017)

The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
por: Madonna, Stefania, et al.
Publicado: (2019)

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies
por: Ganesan, Rajkumar, et al.
Publicado: (2017)

Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN
por: Keermann, Maris, et al.
Publicado: (2015)

Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury
por: Scheiermann, Patrick, et al.
Publicado: (2015)

The severity of experimental arthritis is independent of IL-36 receptor signaling
por: Lamacchia, Céline, et al.
Publicado: (2013)

Generalized pustular psoriasis with a novel mutation of interleukin-36 receptor antagonist, responding to methotrexate
por: Teoh, Yee-Leng, et al.
Publicado: (2015)

Protective effect of interleukin-36 receptor antagonist on liver injury induced by concanavalin A in mice
por: Peng, Xiao, et al.
Publicado: (2020)

IL-36α Exerts Proinflammatory Effects in Aspergillus fumigatus Keratitis of Mice Through the Pathway of IL-36α/IL-36R/NF-κB
por: Niu, Yawen, et al.
Publicado: (2021)

IL-25 exacerbates autoimmune aortitis in IL-1 receptor antagonist-deficient mice
por: Yoshizaki, Takamichi, et al.
Publicado: (2019)

IL-1 Receptor Antagonist (IL-1Ra) Levels and Management of Metabolic Disorders
por: Luotola, Kari
Publicado: (2022)

Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues
por: Conner, Kip P., et al.
Publicado: (2020)

Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice
por: Watanabe, Soichiro, et al.
Publicado: (2020)

Influence of Polymorphism in the Genes for the Interleukin (IL)-1 Receptor Antagonist and IL-1β on Tuberculosis
por: Wilkinson, Robert J., et al.
Publicado: (1999)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Production of interleukin (IL)-1 receptor antagonist by human articular chondrocytes
por: Palmer, G, et al.
Publicado: (2002)

Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine
por: Lombardo, Salvo Danilo, et al.
Publicado: (2019)

Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
por: Villatoro, Alicia, et al.
Publicado: (2023)

Interleukin(IL)-36α and IL-36γ Induce Proinflammatory Mediators from Human Colonic Subepithelial Myofibroblasts
por: Kanda, Toshihiro, et al.
Publicado: (2015)

Role of IL-36γ/IL-36R Signaling in Corneal Innate Defense Against Candida albicans Keratitis
por: Dai, Chenyang, et al.
Publicado: (2021)

Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis
por: Derer, Anja, et al.
Publicado: (2014)

Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)
por: Gschwend, Anna, et al.
Publicado: (2022)

IL-36 cytokines in autoimmunity and inflammatory disease
por: Ding, Liping, et al.
Publicado: (2017)

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
por: Chen, Feier, et al.
Publicado: (2020)

The effect of an interleukin receptor antagonist (IL-1ra) on colonocyte eicosanoid release
por: Smith, G. S., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_emlmk002vvbl3jq7c191iimjs5